Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Common Stock Issued
Cash raised by issuing new shares.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued declines year over year
Q1 FY2026 common stock issued of $24.84M fell 14.8% year over year, ahead of the -56.4% change in trailing-twelve-month common stock issued. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Common stock issued amounted to 706.7% of revenue in FY2025, down 772.0 pp from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -14.8% holds above the trailing-twelve-month pace of -56.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 28.66M USD
- Year-over-year change
- +3.0%
- 4-year CAGR
- -22.1%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.66M | +3.0% |
| FY2024 | 2024-12-31 | 27.81M | +100.9% |
| FY2023 | 2023-12-31 | 13.85M | -57.8% |
| FY2022 | 2022-12-31 | 32.84M | -57.9% |
| FY2021 | 2021-12-31 | 77.99M | — |
Common Stock Issued vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 common stock issued of $24.84M is the 7th largest of the 10 companies compared; the peer median is $90.73M.
- Its year-over-year change of -56.4% is the lowest of 10, against a peer median of +1447.7%.
- Common stock issued amounts to 1274.6% of revenue for IMDX, versus a peer median of 205.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $215.74M | +71102.0% | +650.6% | 386.2% | |
| LTM Mar 2026 | $126.82M | +1104.7% | +445.8% | 363.8% | |
| LTM Mar 2026 | $109.49M | +6044.2% | -1.8% | — | |
| LTM Mar 2026 | $104.89M | +75017.8% | +219.2% | 5879.2% | |
| LTM Mar 2026 | $90.73M | +439.2% | -4.5% | 262.5% | |
| LTM Mar 2026 | $28.32M | +880.3% | -33.5% | 98.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.84M | -56.4% | -4.4% | 1274.6% |
| LTM Mar 2026 | $24.78M | +7477.4% | +213.2% | 148.2% | |
| LTM Mar 2026 | $16.94M | -47.7% | +170.3% | 21.7% | |
| LTM Mar 2026 | $1.36M | +1447.7% | -75.5% | 46.0% | |
| Peer median (excluding IMDX) | $90.73M | +1447.7% | +170.3% | 205.4% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.